BIOBV logo

Biohit Oyj Stock Price

HLSE:BIOBV Community·€44.0m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 4 Fair Values set on narratives written by author

BIOBV Share Price Performance

€2.97
0.71 (31.42%)
€2.97
0.71 (31.42%)
Price €2.97

BIOBV Community Narratives

There are no narratives available yet.

Recent BIOBV News & Updates

Biohit Oyj's (HEL:BIOBV) Promising Earnings May Rest On Soft Foundations

Feb 20
Biohit Oyj's (HEL:BIOBV) Promising Earnings May Rest On Soft Foundations

After Leaping 32% Biohit Oyj (HEL:BIOBV) Shares Are Not Flying Under The Radar

Jan 10
After Leaping 32% Biohit Oyj (HEL:BIOBV) Shares Are Not Flying Under The Radar

Biohit Oyj Key Details

€14.3m

Revenue

€4.6m

Cost of Revenue

€9.6m

Gross Profit

€7.4m

Other Expenses

€2.3m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
0.15
Gross Margin
67.49%
Net Profit Margin
15.88%
Debt/Equity Ratio
0%

Biohit Oyj Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet and good value.

2 Risks
3 Rewards

About BIOBV

Founded
1988
Employees
49
CEO
Jussi Hahtela
WebsiteView website
www.biohithealthcare.com

Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company’s diagnostic tests product includes the GastroPanel Unified test panel for stomach health check; GastroPanel Four-in-One stomach test; GastroSoft software application to assist clinicians and general practitioner; BIOHIT Active B12, a test for measuring the concentration of total vitamin-B12 in the serum; BIOHIT Total 25OH Vitamin D, a test for determination of 25-hydroxyvitamin D2 and D3; and BIOHIT Calprotectin test, a quantitative test that provides a reliable differentiation between inflammatory bowel diseases and irritable bowel syndrome. It also offers GastroPanel quick test NT, a quantitative immunochromatographic test for the detection of Helicobacter pylori (H. Pylori) and atrophic gastritis; BIOHIT Celiac Quick test for diagnosis of celiac disease; Biohit ColonView Quick test, a test for detection of fecal occult blood; Biohit Helicobacter Pylori UFT300 and Helicobacter Pylori Quick test methods to detect H. pylori infection; Gluten Immunogenic Peptides test; and Lactose Intolerance quick test to support the diagnosis of lactose intolerance in a duodenal biopsy specimen. The company provides acetaldehyde-binding products, such as Acetium capsules for protection of stomach; Acetium lozenge, which helps in quitting smoking; and monoclonal antibodies for use in the areas of cellular pathology, neurobiology, oncology, and human gastric biomarkers research. It also offers BIOHIT FAEX for the collection and handling of stool samples; and GP Reader NT, an automated instrument for the quantitative determination of various analytes in human samples, such as whole blood, plasma, or fecal samples by measuring fluorescence signals from lateral flow test cassettes. The company was incorporated in 1988 and is headquartered in Helsinki, Finland.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

Finnish Market Performance

  • 7 Days: 0.6%
  • 3 Months: 4.1%
  • 1 Year: 7.7%
  • Year to Date: 14.3%
Over the last 7 days, the market has remained flat, although notably the Utilities sector gained 4.9% in that time. Meanwhile, the market is actually up 7.7% over the past year. Earnings are forecast to grow by 17% annually. Market details ›